Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd’s shares declined sharply to a new 52-week low of Rs.46 today, marking a significant downturn in the stock’s performance amid broader market fluctuations and company-specific concerns.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Oxygenta Pharmaceutical Ltd’s shares declined sharply to a new 52-week low of Rs.46.6 today, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock’s performance continues to trail the sector and benchmark indices, reflecting ongoing concerns about its financial health and market positioning.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 February 2026, providing investors with the most recent insights into the company’s performance and outlook.

Oxygenta Pharmaceutical Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹226.00 crores, reported a net loss of ₹4.84 crores for Q3 FY26 (October-December 2025), representing a marginal improvement of 1.83% quarter-on-quarter but a 23.16% deterioration year-on-year. The stock, trading at ₹60.00 as of February 5, 2026, declined 1.70% on the day, reflecting investor concerns about the company's persistent inability to achieve profitability despite robust top-line growth.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Oxygenta Pharmaceutical Ltd’s shares declined to a fresh 52-week low of Rs.51.31 on 21 Jan 2026, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and market positioning.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 December 2025, providing investors with the latest insights into its performance and outlook.

Oxygenta Pharmaceutical has reached a new 52-week low of Rs.52.1, marking a significant decline in its stock price amid a broader market downturn. The stock has underperformed its sector and the benchmark indices, reflecting ongoing challenges within the company and the pharmaceuticals sector.

Oxygenta Pharma has experienced a revision in its market evaluation, reflecting shifts in its financial performance and market positioning. This adjustment highlights ongoing challenges within the Pharmaceuticals & Biotechnology sector, particularly for microcap companies facing operational and valuation pressures.

Oxygenta Pharmaceutical has attracted remarkable buying interest today, with the stock hitting an upper circuit and registering only buy orders in the queue. This unusual market behaviour signals a potential multi-day circuit scenario, reflecting strong demand despite recent price pressures and sector trends.

Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with a significant stock increase today, reversing a two-day decline. Despite recent challenges, the stock has shown impressive long-term growth over five years. Current performance metrics indicate mixed technical signals, reflecting ongoing market sentiment and potential sector developments.

Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with the stock rising significantly today, in contrast to a decline in the Sensex. Despite recent challenges, the stock has shown resilience over the past month, outperforming the index, while current trading indicates mixed trends in the short to medium term.